CTMX
CytomX Therapeutics Inc
$
3.880
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
3.940
Open
3.760
VWAP
3.86
Vol
1.78M
Mkt Cap
657.41M
Low
3.725
Amount
6.88M
EV/EBITDA(TTM)
20.95
Total Shares
77.92M
EV
513.78M
EV/OCF(TTM)
--
P/S(TTM)
3.99
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is focused on developing conditionally activated, masked biologics designed to be localized to the tumor microenvironment. The Company is developing a pipeline of localized biologics, through its PROBODY therapeutic platform. Its pipeline comprises therapeutic candidates across multiple treatment modalities, including ADCs, T-cell engagers, and immune modulators such as cytokines. Its clinical-stage pipeline includes CX-2051, CX-904 and CX-801. CX-2051 is a masked, conditionally activated ADC directed toward EpCAM, armed with a topoisomerase-1 inhibitor payload. CX-904 is a masked, conditionally activated T-cell-engaging bispecific antibody targeting the EGFR on tumor cells and the CD3 receptor on T cells. CX-801 is a masked interferon alpha-2b PROBODY cytokine with broad potential applicability in traditionally immuno-oncology-sensitive as well as insensitive (cold) tumors.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q1
FY2025Q4
FY2025Q3
14.79M
-20.73%
-0.100
-137.04%
6.67M
-86.91%
-0.083
-136.17%
7.51M
-80.27%
-0.050
-170.84%
Estimates Revision
The market is revising No Change the revenue expectations for CytomX Therapeutics, Inc. (CTMX) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 83.02%.
Revenue Estimates for FY2025
No Change
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
0.00%
In Past 3 Month
Stock Price
Go Up
+83.02%
In Past 3 Month
7 Analyst Rating
67.53% Upside
Wall Street analysts forecast CTMX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CTMX is 6.50 USD with a low forecast of 3.50 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
1 Hold
0 Sell
Strong Buy
67.53% Upside
Current: 3.880
Low
3.50
Averages
6.50
High
10.00
67.53% Upside
Current: 3.880
Low
3.50
Averages
6.50
High
10.00
H.C. Wainwright
Mitchell Kapoor
Buy
maintain
$5 -> $10
2025-11-11
Reason
H.C. Wainwright
Mitchell Kapoor
Price Target
$5 -> $10
2025-11-11
maintain
Buy
Reason
H.C. Wainwright analyst Mitchell Kapoor raised the firm's price target on CytomX Therapeutics to $10 from $5 and keeps a Buy rating on the shares. The firm says "strong" CX-2051 trial demand and expansion of enrollment to 100 patients should provide a stronger signal for an approval path.
Piper Sandler
NULL -> Overweight
maintain
$5
2025-11-10
Reason
Piper Sandler
Price Target
$5
2025-11-10
maintain
NULL -> Overweight
Reason
Piper Sandler raised the firm's price target on CytomX Therapeutics to $6.50 from $5 and keeps an Overweight rating on the shares. At SITC, CytomX presented Phase I data on Probody masked IFNalpha2b CX-801 in melanoma and preclinical data on Probody CDH3 T-cell engager CX-908. CytomX will present Phase I CX-801 data in combination with KEYTRUDA in advanced melanoma patients next year. Initial Phase I data on Probody masked EpCAM ADC CX-2051 showed doses of 7.2-10mg/kg achieved an impressive 28% ORR, 94% DCR and preliminary mPFS of 5.8 months in 3rd-line+ metastatic colorectal cancer.
Barclays
Etzer Darout
maintain
$6
2025-10-21
Reason
Barclays
Etzer Darout
Price Target
$6
2025-10-21
maintain
Reason
Barclays analyst Etzer Darout raised the firm's price target on CytomX Therapeutics to $6 from $3.50 and keeps an Overweight rating on the shares. The company's data in late-line colorectal cancer compares favorably to peers, the analyst tells investors in a research note.
Cantor Fitzgerald
NULL -> Overweight
initiated
$6
2025-09-22
Reason
Cantor Fitzgerald
Price Target
$6
2025-09-22
initiated
NULL -> Overweight
Reason
Cantor Fitzgerald initiated coverage of CytomX Therapeutics with an Overweight rating and $6 price target.
Cantor Fitzgerald
Overweight
initiated
$6
2025-09-22
Reason
Cantor Fitzgerald
Price Target
$6
2025-09-22
initiated
Overweight
Reason
Cantor Fitzgerald initiated coverage of CytomX Therapeutics with an Overweight rating and $6 price target. CytomX may have a real contender on its hands with CX-051, a masked epithelial cell adhesion molecule antibody-drug conjugate, and one it can build a franchise around, the analyst tells investors in a research note. Cantor likes the setup, saying that if CX-2051 delivers, CytomX owns a first-in-class space with blockbuster potential in colorectal cancer, and optionality well beyond that.
Barclays
initiated
$3.50
2025-09-16
Reason
Barclays
Price Target
$3.50
2025-09-16
initiated
Reason
Barclays initiated coverage of CytomX Therapeutics with an Overweight rating and $3.50 price target.
See All Ratings
Valuation Metrics
The current forward P/E ratio for CytomX Therapeutics Inc (CTMX.O) is -10.76, compared to its 5-year average forward P/E of 13.22. For a more detailed relative valuation and DCF analysis to assess CytomX Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
13.22
Current PE
-10.76
Overvalued PE
83.90
Undervalued PE
-57.46
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-0.52
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
10.61
Undervalued EV/EBITDA
-11.64
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
3.38
Current PS
0.00
Overvalued PS
6.76
Undervalued PS
0.01
Financials
Annual
Quarterly
FY2025Q3
YoY :
-82.16%
5.96M
Total Revenue
FY2025Q3
YoY :
-483.56%
-15.77M
Operating Profit
FY2025Q3
YoY :
-348.06%
-14.23M
Net Income after Tax
FY2025Q3
YoY :
-228.57%
-0.09
EPS - Diluted
FY2025Q3
YoY :
-100.00%
N/A
Free Cash Flow
FY2025Q3
YoY :
0.00%
100.00
Gross Profit Margin - %
FY2025Q3
YoY :
-9.20%
-63.67
FCF Margin - %
FY2025Q3
YoY :
-1490.56%
-238.62
Net Margin - %
FY2025Q3
66.76
ROIC
Trading Trends
Insider
Insiders areSelling! The selling amount has increased 359.35% over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
220.0K
USD
4
6-9
Months
47.9K
USD
5
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 1979% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
3
20.8M
Volume
Months
6-9
1
1,000K
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders areSelling! The selling amount has increased 359.35% over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
220.0K
USD
4
6-9
Months
47.9K
USD
5
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
CTMX News & Events
Events Timeline
2025-11-06 (ET)
2025-11-06
17:09:56
CytomX Therapeutics Announces Q3 Earnings Per Share of 9 Cents, Exceeding Consensus Estimate of 4 Cents
2025-10-20 (ET)
2025-10-20
16:38:38
CytomX Therapeutics names Rachael Lester as chief business officer
2025-10-14 (ET)
2025-10-14
12:12:36
Oppenheimer Optimistic About CytomX Following Merus Colon Cancer Results
Sign Up For More Events
Sign Up For More Events
News
6.5
14:10 PMYahoo FinanceAnalysts Discuss the Evolving CytomX Narrative Following Recent Clinical Progress and Increased Price Target
4.0
11-11BenzingaHC Wainwright & Co. Reaffirms Buy Rating for CytomX Therapeutics and Increases Price Target to $10
9.0
11-07SeekingAlphaCytomX announces Q1 2026 data update for CX-2051 and achieves 100-patient enrollment milestone as Phase Ib study progresses.
Sign Up For More News
People Also Watch
CVU
CPI Aerostructures Inc
2.800
USD
+5.26%
UNCY
Unicycive Therapeutics Inc
5.400
USD
+2.47%
GTI
Graphjet Technology
0
USD
-44.07%
USEG
US Energy Corp
0.982
USD
+2.61%
AUID
Authid Inc
1.340
USD
-21.64%
WPRT
Westport Fuel Systems Inc
1.580
USD
+2.60%
LOAN
Manhattan Bridge Capital Inc
4.540
USD
+3.18%
CLPR
Clipper Realty Inc
3.620
USD
+1.69%
FAQ
What is CytomX Therapeutics Inc (CTMX) stock price today?
The current price of CTMX is 3.88 USD — it has increased 2.92 % in the last trading day.
What is CytomX Therapeutics Inc (CTMX)'s business?
What is the price predicton of CTMX Stock?
What is CytomX Therapeutics Inc (CTMX)'s revenue for the last quarter?
What is CytomX Therapeutics Inc (CTMX)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for CytomX Therapeutics Inc (CTMX)'s fundamentals?
How many employees does CytomX Therapeutics Inc (CTMX). have?